VIAVI Solutions Inc. has introduced its second-generation RSR Transcoder, engineered to maintain operational capability in GPS/GNSS-denied, degraded or disrupted space operational environments. This ...

BOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today ...

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and ...

CHANDLER, Ariz., May 28, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today announced the launch of its second-generation RSR Transcoder, created to maintain operational ...

BOSTON, May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of $5.73 million specializing in RNA-targeted cancer treatments, announced today the ...

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode ...

On Display at the Joint Navigation Conference Last week also saw VIAVI launch its second generation RSR Transcoder with GPS full constellation simulator, which is designed to give assured PNT ...